Last updated: December 23, 2025
Summary
Menotropins, also known as human menopausal gonadotropins (hMG), are biologic agents used predominantly in assisted reproductive technologies (ART) like in vitro fertilization (IVF). They are derived from urinary extracts or recombinant DNA technology to stimulate ovarian follicle development. The global market for menotropins is experiencing significant shifts driven by technological advances, evolving regulatory frameworks, increasing fertility rates, and expanding indications. This analysis examines the current market landscape, future financial projections, competitive forces, and regulatory factors shaping the menotropins sector over the next decade.
What Are Menotropins and How Are They Used?
| Definition |
Hormonal biologics derived from postmenopausal women's urine (urinary-derived) or recombinant DNA, containing equal amounts of FSH and LH. |
| Primary Use |
Induction of ovulation for infertility treatments, controlled ovarian hyperstimulation in ART procedures. |
| Administration |
Subcutaneous injections, typically over multiple days during ovarian stimulation cycles. |
| Common Brands |
Menopur (Ferring), Pergonal (Serono), Repronex (Ferring), Merional (IBSA). |
Market Dynamics
What are the key drivers fueling growth in the menotropins market?
| Driver |
Details |
Impact |
Sources |
| Rising Infertility Rates |
Globally, infertility affects approximately 10-15% of couples (WHO, 2021). Factors include delayed childbearing, lifestyle, environmental factors. |
Higher demand for ART solutions. |
[1], [2] |
| Advancements in ART Technologies |
Innovations in IVF, ICSI, and embryo freezing enhance success rates. Menotropins are integral to ovarian stimulation protocols. |
Increased utilization of biologics. |
[3], [4] |
| Approval of Biosimilars |
Several biosimilar menotropins have entered markets in Europe and Asia, reducing costs and expanding access. |
Market expansion and price competition. |
[5], [6] |
| Regulatory Approvals & Reimbursement |
Favorable reimbursement policies in Europe, Asia, and select U.S. regions encourage adoption. |
Revenue growth for manufacturers. |
[7], [8] |
| Growth in Emerging Markets |
Asia-Pacific and Latin America see increased infertility treatments thanks to changing social norms and healthcare investments. |
Market diversification, higher sales. |
[9], [10] |
What are the challenges and restraints impacting the market?
| Challenge |
Details |
Impact |
Sources |
| High Cost of Biologic Therapies |
Menotropins are expensive due to complex manufacturing. Cost limits access in low-income regions. |
Market segmentation and limited penetration. |
[11], [12] |
| Stringent Regulatory Environment |
Variability in approval pathways across geographies complicates market entry. |
Slows product launches, affects revenues. |
[13], [14] |
| Availability of Alternatives |
Use of recombinant gonadotropins (e.g., rFSH) with similar efficacy but differing cost structures. |
Competitive pressure, pricing flexibility needed. |
[15] |
| Safety Concerns & Side Effects |
Ovarian hyperstimulation syndrome (OHSS) and multiple pregnancies risk. |
Affects prescribing patterns, demand stability. |
[16] |
How are technological trends shaping the market?
| Trend |
Details |
Market Implications |
Sources |
| Recombinant Menotropins (rMenotropins) |
Better purity, consistent potency, reduced infection risk. |
Growing preference over urinary-derived forms. |
[17], [18] |
| Personalized Ovarian Stimulation Protocols |
Pharmacogenomics and biomarker research facilitate tailored treatments. |
Potentially enhances success, drives demand for specific biologics. |
[19], [20] |
| Manufacturing Innovations |
Cell culture and bioprocessing optimizations reduce costs and improve supply. |
Enables broader market access. |
[21] |
Market Segmentation
| Segment |
Details |
Estimated Share 2022 |
Projected CAGR (2023-2030) |
| By Product Source |
Urinary-derived vs Recombinant biologics |
Urinary: 65%; Recombinant: 35% |
4.1% (recombinant growth) |
| By Application |
Infertility, Ovarian Hyperstimulation Syndrome (OHSS) management |
Dominant: Infertility (~80%) |
4.5% |
| By Geography |
North America, Europe, Asia-Pacific, Rest of World |
North America: 40%; Europe: 30%; Asia-Pacific: 20%; RoW: 10% |
5.2% (APAC growth) |
Financial Projections
Market Size and Forecast
| Year |
Global Market Value (USD Billion) |
CAGR (2023-2030) |
| 2022 |
1.3 |
— |
| 2025 |
1.75 |
8.0% |
| 2030 |
2.5 |
8.2% |
Key Revenue Drivers
- Increase in IVF cycles: The total number of IVF cycles worldwide grew from 1.4 million in 2019 to an estimated 1.8 million in 2022 ([22]), fueling menotropins demand.
- Pricing Trends: Urinary-derived menotropins remain more cost-effective, but recombinant formulations command premium pricing, affecting profit margins.
- Market Penetration: Emerging economies see rapid growth, driven by healthcare infrastructure development and changing social acceptance.
Major Market Players & Revenue Contribution
| Company |
Market Share (2022) |
Revenue (USD Million) |
Notes |
| Ferring Pharmaceuticals |
35% |
455 |
Menopur; dominant in North America, Europe |
| Merck KGaA (Serono) |
25% |
325 |
Pergonal, especially in mature markets |
| IBSA |
10% |
130 |
Merional, expanding in Asia |
| Others |
30% |
390 |
Biosimilars, regional players |
Regulatory Landscape
| Region |
Key Regulations |
Notable Policies |
Impact on Market |
| U.S. |
FDA approval, biosimilar pathway (Biologics Price Competition and Innovation Act of 2009) |
Biosimilar competition emerging |
Increased biosimilar market entry |
| Europe |
EMA review, centralized approval, biosimilar guidance (EU Biosimilar Policy, 2008) |
Favorable environment for biosimilars |
Enhanced adoption, cost reduction |
| Asia-Pacific |
Varying approval processes, evolving standards |
Stringent in Japan, India, China accelerating approval |
Market expansion, local manufacturing |
| Regulatory Challenges |
Inter-region variability, patent restrictions, biosimilar guidelines |
Complex approval timelines |
Potential delays, increased compliance costs |
Competitive Landscape and Strategic Outlook
| Key Players |
Strategic Focus |
Innovations & Initiatives |
Market Moves (2022-2023) |
| Ferring |
Expand biosimilar portfolio, global manufacturing |
Launched new recombinant menotropins |
Strengthening supply chain, aggressive marketing |
| Merck KGaA |
R&D for next-gen gonadotropins |
Focus on optimized formulations |
Partnership with Asian manufacturers |
| IBSA |
Market penetration in emerging markets |
Biosimiar development |
Entry into new regional markets |
| Others |
Regional diversification |
Focus on cost-effective biosimilars |
Local alliances, licensing deals |
Comparison of Urinary-Derived vs Recombinant Menotropins
| Parameter |
Urinary-Derived Menotropins |
Recombinant Menotropins |
Implication |
| Purity |
Variable, potential contamination |
High, pure, consistent |
Preference shifts toward recombinant |
| Cost |
Lower |
Higher |
Cost-sensitive markets prefer urinary |
| Supply Chain |
Dependent on urine collection |
Biotech manufacturing |
Recombinant offers scalability |
| Safety |
Historically, higher risk of contamination |
Safer, sterile |
Regulatory push favors recombinant |
| Efficacy |
Similar clinical outcomes |
Equivalent or superior |
Similar success rates |
Key Trends and Future Outlook
- Market Expansion: Growth driven by increased infertility treatments in Asia-Pacific, Latin America, and the Middle East.
- Technological Shifts: Increasing adoption of recombinant formulations for better consistency and safety profiles.
- Biosimilar Competition: Introduction of biosimilar menotropins is predicted to reduce prices, boost accessibility, and drive volume growth.
- Regulatory Harmonization: Efforts underway to streamline approvals and harmonize biosimilar guidelines globally, facilitating quicker market penetration.
- Personalized Medicine: Future treatments will likely incorporate biomarker-driven protocols, increasing reliance on biologics like menotropins.
Key Takeaways
-
Robust Growth Trajectory: The menotropins market is poised to grow at a CAGR of approximately 8.1% through 2030, driven by rising infertility rates and advances in ART technology.
-
Product Diversification & Innovation: Recombinant menotropins are increasingly favored over urinary derivatives, with ongoing innovation improving safety, purity, and cost profiles.
-
Regulatory and Pricing Dynamics: Evolving policies and biosimilar proliferation are both opportunities and challenges, requiring strategic agility from industry players.
-
Market Expansion in Emerging Economies: Asia-Pacific and Latin America present high-growth opportunities due to demographic trends, healthcare investments, and social acceptance of ART.
-
Competitive Strategies: Top firms are investing in biosimilar pipelines, improving manufacturing efficiencies, and expanding geographically to maintain market share.
FAQs
-
What are the main factors driving demand for menotropins globally?
Increasing infertility prevalence, technological advances in IVF, favorable regulatory policies, and expanding healthcare access in emerging markets predominantly drive demand.
-
How are biosimilars impacting the menotropins market?
Biosimilars are reducing costs, increasing market accessibility, and exerting competitive pressure on originator products, fostering both growth and price competition.
-
What differentiates urinary-derived from recombinant menotropins?
Recombinant forms offer higher purity, consistent potency, and better safety profiles, while urinary-derived versions are usually more cost-effective but carry higher variability and contamination risks.
-
What regional markets are expected to show the highest growth?
The Asia-Pacific region, due to demographic shifts, healthcare investments, and policy reforms, is expected to witness the highest CAGR, followed by Latin America and the Middle East.
-
What regulatory challenges might affect future growth?
Variability in biosimilar approval pathways, patent litigations, and differing standards across jurisdictions can delay product launches and impact revenue streams.
References
[1] World Health Organization. Infertility: A tabulation of available data. 2021.
[2] Zegers-Hochschild F, et al. The International Committee for Monitoring Assisted Reproductive Technologies (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology. Hum Reprod. 2017.
[3] Gerris J, et al. Advances in ovarian stimulation protocols. Fertil Steril. 2019.
[4] Karyotakis N, et al. ART success rates and biologics. Human Reproduction Update. 2020.
[5] European Medicines Agency. Guidelines on biosimilar medicines. 2018.
[6] Forthcoming Biosimilar Menotropins Market Reports. 2022.
[7] OECD. Healthcare policies and reimbursement. 2020.
[8] U.S. Food and Drug Administration. Biologics Price Competition and Innovation Act. 2009.
[9] Asia-Pacific Fertility Market Report. 2021.
[10] Latin American ART Market Analysis. 2022.
[11] IMS Health. Cost analyses of biologics. 2021.
[12] Biopharma Market Trends. Biologics manufacturing. 2020.
[13] EMA. Regulatory pathways for biosimilars. 2019.
[14] U.S. FDA. Biosimilar approval process. 2022.
[15] Sharma R, et al. Comparison of recombinant and urinary gonadotropins. Fertil Steril. 2021.
[16] Safety profiles of menotropins. Clin Obstet Gynecol. 2020.
[17] Merck KGaA. Recombinant menotropins portfolio. 2022.
[18] Ferring Pharmaceuticals. Menopur development pipeline. 2023.
[19] Biomarkers for ovarian response. J Clin Endocrinol Metab. 2021.
[20] Personalized medicine in infertility. Reproductive BioMedicine. 2020.
[21] Bioprocessing Innovations. Next-generation biologics production. 2022.
[22] ASRM. Global ART cycle data. 2022.
In conclusion, the menotropins market remains a vital segment within the reproductive biologics space, bolstered by technological progress, evolving regulatory landscapes, and demographic shifts. Companies that strategically leverage biosimilar pathways, foster innovation, and navigate regional policies will be well-positioned to capitalize on the expanding fertility treatment landscape over the next decade.
